gretel
25 Apr 2017
Good trading update today [link] have retained their 28p price target for the moment.Today's was a perfectly good trading update in every way - profits nicely in line, CD$ progressing well and Allersys and allergens also advancing. It's also good to see the Indian production facility going so smoothly - there were a lot of factors which could have gone wrong. The malaria test should be a big winner in the months and years ahead, whilst Food Intolerance will only continue to grow.There should be further news flow to come on the IDH tie-up and CD4 progress. I can see that there was no single catalyst in today's statement to keep the short-termers interested, but over time there's certainly the prospect of a multibagger from here imho.
gretel
21 Apr 2017
RNS : Sneller buys and goes above 13% Good stuff. Sneller has added 1.13m shares in the last 6 weeks. It's a huge personal commitment - 14.19m shares must have cost him at least £2.5m to date:[link]
gretel
10 Apr 2017
Nice mention in HYG results HYG announced their 2016 results this morning. They have 2.29m shares in ODX (they sold just 138k last year purely to finance other investments) and concluded thus FYI:[link] summary, the group currently has two key projects, each of which has transformational growth potential to augment the growth potential of the existing established businesses.Update since 2015: both of the transformational projects are progressing and the IDS-iSYS project achieved CE marking for its first panel of 41 allergens in 2016, with a long-term supply contract currently being finalised with the first customer, which is in Germany - in addition, CE-Marked malaria and pregnancy tests are due to be available for sale by Q2 2017. The interim results to September 2016 showed sales of £6.8 million (2015: £6.15 million) and adjusted pre-tax profit of £417,000 (2015: £351,000)."
gretel
29 Mar 2017
RNS : good news re new malaria test RNS this morning re successful compliance for the Indian facility, and most importantly CE marking of the Visitect Malaria Test.In particular, ODX anticipate some sales already for this coming year and then "siginificant demand" after that....[link]
gretel
28 Mar 2017
New recent highs now Moving up strongly. 80k bought at 24.9p just now....and the 100k at 24p could be a buy reported late from early this morning.
gretel
07 Mar 2017
RNS : Sneller buying more, above 12% Richard Sneller is a man in a hurry - he's bought another 350,000 shares since his last RNS and now has 13.05m, going above 12% per today's RNS:[link]
The Specialist
06 Mar 2017
ODX UP 9% - CD4 NEWS IMPENDING? I donot think that the stock would move on developments on IDS by 9% - therefore hoping that we are going to get a major positive update from CD4. Once NGO's also start buying it then we have to say - hello 90p - here we come.
The Specialist
01 Mar 2017
Stock going up - something knows something This stock always goes up before an announcement - I hjave owned it for nearly 4 years and the trend is always the same. In the next few days expect to hear about a potential sale of IDS or a joint venture or more psoitively on developments on CD4. On commercial manufacturing and assuming sales of 7m unitis of CD4 at £5 each then based on sector average multiple we will see the stock in the 70-90p range. The future is indeed good for this company.
gretel
28 Feb 2017
RNS : Richard Sneller buys more ODX He's bought another 1.25m shares since November and is above 11% now.Remember, this is the head of equities at Baillie Gifford buying for his own personal account.
gretel
27 Jan 2017
RNS: IDG want to enlarge relationship Today's RNS confirming that IDH wants an "enlarged" distribution relationship with ODX is a vote of confidence in the company's products:[link] doesn't appear to be any froth at all in the share price from anyone hopefully expecting a multi-million pound sale of the allergy business, so no-one sould be too disappointed.
Ambiorix1
11 Jan 2017
News to come Today III is going to tell us that ODX produced its first malaria test and also that the PUNE facility got its accreditation which means ODX can start selling its diagnostics tests in India.Strange. Someone must have known this a bit sooner. Yesterday + 1 million shares were traded. Ambiorix.
gretel
11 Jan 2017
Good news re the new Inidian facility and the first commercial malaria sales have been achieved:[link] accreditation for manufacturing facility in Pune, IndiaOmega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that its fully owned Indian subsidiary, Omega Dx (Asia) Pvt. Ltd has received certificates of accreditation from BSI confirming its Quality Management System is compliant with ISO 9001:2008 and ISO 13485:2003.The accreditation covers the manufacturing facility in Pune and ensures that product originating from this site is designed, manufactured and supplied to internationally recognised quality standards. This milestone is an important pre-requisite for CE-Marking the malaria and pregnancy tests produced at this site. CE-Marking is still expected to be achieved by the end of the current financial year.Accreditation also means that products can be supplied for the Indian domestic market with immediate effect and the first commercial sale of one of the Company's malaria tests has now been achieved.Andrew Shepherd, Chief Executive Officer of the Company commented: "We are pleased to have reached this milestone on schedule and look forward to generating a return from the investment to date in this facility."
gretel
25 Nov 2016
Nice mention here Nice mention here:[link] "HIV Infections and Cytomegalovirus Infection Boost the Mononucleosis Diagnostic Market as People Suffering those Diseases November 25th, 2016Mononucleosis or mono is a common infectious disease caused by Epstein-Barr virus (EBV) also known as human herpesvirus 4, which belongs to gamma herpes virus family. The common symptoms of mono are high fever, sore throat, swollen lymph glands, tonsils and weakness..... .....Some of the commercially available mono diagnostic kits are EBV NA IgG EIA Kit marketed by Bio-Rad, AVITEX IM kit by Omega Diagnostics, VIDAS EBV marketed by bioMérieux Clinical Diagnostics and LIAISO NEBV IgM by DiaSorin. The mononucleosis diagnostic is a growing market with tremendous opportunities. The market is expected to proliferate in coming years owing to significant increase in viral infection in the developed as well as developing countries. The major growth driver for mononucleosis testing includes introduction of new technologies enabling tests to be done in short duration of time, government and public awareness initiatives on mononucleosis infection, and rise in the adolescent population particularly in the South East Asia. Large number of peoples suffering from other diseases with clinically similar symptoms such as strep throat, HIV infections and cytomegalovirus infection would also boost the market as people suffering from those diseases will also go for mono test. etc"
gretel
24 Nov 2016
RNS : Richard Sneller continues to buy Buying quickly too - another almost 2.5m shares. He now has over 10%, with 11.45m shares:[link]
gretel
22 Nov 2016
Interview with FD and MD Encouraging comments here from the FD and MD (Andrew Shepherd). I wonder what the share price will be once the market latches on to the possibility of $115m of revenues from CD4 kits. Just a fraction of that would do wonders for a small cap like ODX....[link] Harbinson finance director: “It’s clearly early days; there needs to be an engagement programme with IDS. We will examine all options, but the fact they have made an approach tells us they recognise the value of the asset we’ve created over the past five years. Until there is clarification we will continue to develop the range of tests.” In October Omega CE-Marked its allergy launch panel, comprising 41 allergens which are capable of being run on IDS’ iSYS instrument. There are plans to grow this number to 120 – for which it received a £1.8m grant from Scottish Enterprise in August. The company has also made “significant progress” with its Visitect CD4 product. After lengthy delays, the tool for determining in the field whether HIV patients require retroviral drug treatment, has now been tested in more than 500 patients in three UK hospitals. Production will now commence on 10,000 devices for external field trials in India, France and sub-Saharan Africa. “A lot of data is going to come from these studies in the first calendar quarter,” said Mr Shepherd. “It takes some time to verify all that data so we’re expecting at the moment we’ll be launching the product with a CE-Marking in the second half of calendar 2017.” The World Health Organisation has estimated that around 22 to 23 million CD4 kits could be required per year, retailing at $5. “There is a significant market out there and everyone we speak to in this global health arena is saying we need this product, we need it desperately, right down at field level,” said Mr Shepherd. The company’s allergy and autoimmune division saw sales grow 11 per cent to £1.76m, while its infectious disease division grew sales by one per cent to £1.23m. In this area its Pune site in India is now producing Malaria point of care kits, which Mr Shepherd said would drive growth in that division. “We’ve invested £1m in Pune and it’s now time for that to start generating a commercial return,” said Mr Harbison. “Malaria will be first but we’ve got a pipeline of future products to come of that facility.” Its food intolerance division grew 15 per cent to £3.84m, driven by ongoing success in the US. Omega also noted growth in Middle East and India, where sales grew 46 per cent. "
